Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer.

Trial Profile

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2017 Results (n=15) exploring changes in cerebrospinal fluid circulating tumor cells enumeration in response to treatment presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Apr 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top